News & Updates

Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduces 3-year risks of major adverse cardiac events (MACE) and all-cause mortality in patients with type 2 diabetes (T2D) and coronary ischaemia, irrespective of the completeness of revascularization, researchers from the University of Hong Kong (HKU) have reported.

Clostridioides difficile infection (CDI) is possible in children with no previous exposure to antibiotics, especially in community settings, suggests a Japan study, supporting the consideration of changes to current management practices for paediatric CDI.